QUOIN PHARMACEUTICALS LT-ADR (QNRX) Forecast, Price Target & Analyst Ratings
NASDAQ:QNRX • US74907L4095
8.09 USD
-0.4 (-4.71%)
At close: Mar 12, 2026
8.2411 USD
+0.15 (+1.87%)
Pre-Market: 3/13/2026, 8:23:49 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for QUOIN PHARMACEUTICALS LT-ADR (QNRX).
Forecast Snapshot
Consensus Price Target
$42.50
+ 425.34% Upside
Next Earnings Forecast
Release DateMay 11, 2026
PeriodQ4 / 2025
EPS Estimate-$3.40
Revenue Estimate
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$42.50
Upside
+ 425.34%
From current price of $8.09 to mean target of $42.50, Based on 8 analyst forecasts
Low
$25.25
Median
$30.60
High
$73.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for QNRX. The average price target is 42.5 USD. This implies a price increase of 425.34% is expected in the next year compared to the current price of 8.09.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
QNRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about QNRX.
In the previous month the buy percentage consensus was at a similar level.
QNRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-03-15 | Maxim Group | Maintains | Buy -> Buy |
| 2022-09-07 | Alliance Global Partners | Initiate | Buy |
| 2022-05-06 | Ladenburg Thalmann | Initiate | Buy |
| 2022-01-07 | Maxim Group | Initiate | Buy |
| 2021-12-15 | JMP Securities | Initiate | Market Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 11, 2026
PeriodQ4 / 2025
EPS Estimate-$3.40
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q72.22%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
QNRX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -3.4 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 474.03% | N/A 99.41% | N/A 25.69% | N/A 59.08% | N/A 28.14% | ||||||||
| EBITDA YoY % growth | N/A | N/A | -8.014M | -6.045M 24.58% | -3.861M 36.12% | -5.959M -54.33% | -9.154M -53.61% | -9.275M -1.32% | -9.429M -1.66% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A -57.89% | -8.142M -17.49% | -6.271M 22.98% | -4.07M 35.09% | -6.063M -48.95% | -9.258M -52.69% | -9.379M -1.30% | -9.529M -1.60% | N/A -70.93% | N/A -30.19% | N/A 93.50% | N/A 3,151.19% | N/A 37.78% | N/A 81.67% | N/A 33.86% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A -64.36% | N/A | N/A | N/A | N/A | -2,977.80 88.57% | -358.40 87.96% | -81.20 77.34% | N/A 78.26% | N/A 64.00% | N/A 91.65% | N/A 6,069.23% | N/A 45.72% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.40 72.22% | -2.00 69.24% | -2.31 63.29% | -1.12 83.28% | -1.14 66.43% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.237M -76.17% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.85%
EPS Next 5 Year
20.76%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
QUOIN PHARMACEUTICALS LT-ADR / QNRX Forecast FAQ
What is the average price target for QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
8 analysts have analysed QNRX and the average price target is 42.5 USD. This implies a price increase of 425.34% is expected in the next year compared to the current price of 8.09.
Can you provide the upcoming earnings date for QUOIN PHARMACEUTICALS LT-ADR?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2026-05-11.
Can you provide the consensus estimates for QUOIN PHARMACEUTICALS LT-ADR next earnings?
The consensus EPS estimate for the next earnings of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is -3.4 USD and the consensus revenue estimate is 0 USD.